Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwenaelle Gravis

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Asian Journal of Urology|May 8, 2019
Systemic treatment for metastatic prostate cancerGwenaelle Gravis
Bulletin Du Cancer|January 23, 2015
[Metastatic hormone-sensitive prostate cancer]Gwenaelle Gravis, Naji Salem, Jochen Walz
European Urology Focus|December 12, 2018
The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate CancerMichael Jonathan Kucharczyk, Gwenaelle Gravis, Tamim Niazi
Bulletin Du Cancer|September 13, 2007
[Prostate cancer and chemotherapy]Gwenaelle Gravis, Naji Salem, Franck Bladou, et al.
World Journal of Surgical Oncology|October 1, 2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-upMathilde Guerin, Naji Salem, Jochen Walz, et al.
Anti-Cancer Drugs|June 22, 2007
Medullary thyroid cancer treated by capecitabineSana Intidhar Labidi, Gwenaelle Gravis, Carole Tarpin, et al.
Cancers|April 12, 2022
The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French SurveyPatricia Marino, Rajae Touzani, Jihane Pakradouni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 29, 2020
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancerMichael J Kucharczyk, Jonathan So, Gwenaelle Gravis, et al.
Bulletin Du Cancer|May 23, 2013
[Pharmaco and diet based prostate cancer prevention]François Eisinger, Géraldine Cancel-Tassin, Abdel Rahmene Azzouzi, et al.
Frontiers in Immunology|October 3, 2022
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case reportRoxane Mari, Mathilde Guerin, Cécile Vicier, et al.
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Asian Journal of Urology|May 8, 2019
Systemic treatment for metastatic prostate cancerGwenaelle Gravis
Bulletin Du Cancer|January 23, 2015
[Metastatic hormone-sensitive prostate cancer]Gwenaelle Gravis, Naji Salem, Jochen Walz
European Urology Focus|December 12, 2018
The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate CancerMichael Jonathan Kucharczyk, Gwenaelle Gravis, Tamim Niazi
Bulletin Du Cancer|September 13, 2007
[Prostate cancer and chemotherapy]Gwenaelle Gravis, Naji Salem, Franck Bladou, et al.
World Journal of Surgical Oncology|October 1, 2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-upMathilde Guerin, Naji Salem, Jochen Walz, et al.
Anti-Cancer Drugs|June 22, 2007
Medullary thyroid cancer treated by capecitabineSana Intidhar Labidi, Gwenaelle Gravis, Carole Tarpin, et al.
Cancers|April 12, 2022
The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French SurveyPatricia Marino, Rajae Touzani, Jihane Pakradouni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 29, 2020
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancerMichael J Kucharczyk, Jonathan So, Gwenaelle Gravis, et al.
Bulletin Du Cancer|May 23, 2013
[Pharmaco and diet based prostate cancer prevention]François Eisinger, Géraldine Cancel-Tassin, Abdel Rahmene Azzouzi, et al.
Frontiers in Immunology|October 3, 2022
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case reportRoxane Mari, Mathilde Guerin, Cécile Vicier, et al.
Pageof 15